263 related articles for article (PubMed ID: 35088492)
1. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL
Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492
[TBL] [Abstract][Full Text] [Related]
2. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
3. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
[TBL] [Abstract][Full Text] [Related]
4. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
5. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for people with multiple sclerosis.
Filippini G; Kruja J; Del Giovane C
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Li H; Hu F; Zhang Y; Li K
J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
[TBL] [Abstract][Full Text] [Related]
9. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
11. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
13. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
[TBL] [Abstract][Full Text] [Related]
14. Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota.
Pilotto S; Zoledziewska M; Fenu G; Cocco E; Lorefice L
Mult Scler Relat Disord; 2023 May; 73():104671. PubMed ID: 37001407
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database.
Stamatellos VP; Siafis S; Papazisis G
Br J Clin Pharmacol; 2021 Dec; 87(12):4769-4779. PubMed ID: 33998034
[TBL] [Abstract][Full Text] [Related]
16. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
17. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
18. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
MacDonald SC; McElrath TF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
[TBL] [Abstract][Full Text] [Related]
19. Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA.
Hartung DM
Curr Neurol Neurosci Rep; 2021 May; 21(7):28. PubMed ID: 33948740
[TBL] [Abstract][Full Text] [Related]
20. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]